What is Orgenesis?
Orgenesis operates at the intersection of biotechnology and decentralized manufacturing, focusing on the accessibility of cell and gene therapies (CGTs). The company's core value proposition is the POCare Platform, a tripartite ecosystem consisting of therapeutic pipelines, automated production technologies, and a collaborative global network. By shifting the production paradigm from centralized, high-cost facilities to decentralized, automated systems, Orgenesis aims to lower the barrier to entry for life-saving treatments. This model facilitates a harmonized pathway for clinical development, effectively bridging the gap between research innovation and patient-centric delivery in hospitals and research institutions worldwide.
How much funding has Orgenesis raised?
Orgenesis has raised a total of $55M across 2 funding rounds:
Unspecified
$50M
Private Equity
$5M
Unspecified (2022): $50M with participation from Metalmark Capital
Private Equity (2023): $5M led by Metalmark Capital Partners
Key Investors in Orgenesis
Metalmark Capital
Metalmark Capital is a growth equity investment firm that focuses on founder-owned businesses in the middle market, aiming to build long-term value through active and collaborative partnerships.
Metalmark Capital Partners
An investment firm specializing in private equity and strategic growth capital for companies with significant market potential.
What's next for Orgenesis?
Looking ahead, the strategic deployment of these funds will likely focus on the expansion of the POCare Network and the optimization of its automated production systems. As the biotech sector faces increasing pressure to reduce costs while maintaining rigorous regulatory standards, Orgenesis is positioned to capture significant market share by providing a scalable, decentralized infrastructure. Future growth will likely involve deepening partnerships with research institutes and clinical providers to standardize the production of complex therapies, thereby solidifying the company's role as a critical enabler in the next generation of personalized medicine.
See full Orgenesis company page
